Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 1013-1018

  Zhong, Haijun ^a   Zhang, Yiping ^a   Ma, Shenglin ^a   Ying, Jie Er ^a   Yang, Yunshan ^a   Yong, Dong ^a   Hang, Xiaosheng ^b   Sun, Qing ^c   Zhong, Baoliang ^e   Wang, Daoyuan ^d  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Advanced gastric cancer; Docetaxel; Oxaliplatin; Salvage chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOCETAXEL PLUS OXALIPLATIN; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; EPTAPLATIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PLATINUM; UFT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER MORTALITY; CHINESE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG MEGADOSE; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; SAFETY; SCORING SYSTEM; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TIME; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TAXOIDS;

EID: 54249125607     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328314b5ab     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72:37-41.
3. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995; 71:587-591.
4. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anti-Cancer Drugs 1996; 7:137-149.
5. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
6. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80:269-272.
7. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261-267.
8. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-3818.
9. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 2000; 11:301-306.
10. Ridwelski K, Gebauer T, Fahlke J, Kröning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12:47-51.
11. Woynarowsk JM, Faivre S, Herzig MC, Woynarowski JM, Faivre S, Herzig M, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58:920-927.
12. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993; 53:799-808.
13. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54:3500-3505.
14. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marry M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25:299-303.
15. Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, et al. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 2005; 55:595-601.
16. Agelaki S, Kouroussis C, Mavroudis D, Kalbakis K, Souglakos J, Reppa D, et al. A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer and non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19:abstract 443.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10:1-10.
18. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909.
19. Taguchi T. A late phase II study of docetaxel in patients with gastric cancer. Proceedings of the ASCO 1997; 15:abstract 934.
20. Vanhoefer U. Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer. Proc Am Soc Clin Oncol 1999; 18:(abstract 1163).
21. Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008; 61:631-637.
22. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 2004; 27:477-480.
23. Kim H, Park JH, Bang SJ, Kim DH, Cho HR, Kim GY, et al. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Jpn J Clin Oncol 2005; 35:727-732.
24. Kunisaki C, Imada T, Yamada R, Hatori S, Ono H, Otsuka Y, et al. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 2005; 25:2973-2977.
25. Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E, et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer 2007;10:104-111.
26. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabrai Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005; 23:5660-5667.
27. Fahlke J, Ridwelski K, Schmidt C, Hribaschek K, Stuebs P, Kettner E, et al. A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer. Chemotherapy 2007; 53:454-460.
28. Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol 2007; 59:17-21.
29. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol 2008; 19:104-108.
30. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, et al. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer 2008; 98:542-546.
31. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
32. Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, et al. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 2007; 37:936-941.
33. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, et al. Combination chemotherapy with capecitabine(X) and cisplatin(P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 2007; 37:30-37.